Investor Relations

Tear Sheet

Company Profile

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with Alzheimer’s disease and as an adjunctive treatment for Major Depressive Disorder, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Corporate

BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com

Investor

FTI Consulting
Matt Ventimiglia
T: 212-850-5624
matthew.ventimiglia@fticonsulting.com

Media

FTI Consulting
Helen O'Gorman
T: 718-408-0800
helen.ogorman@fticonsulting.com

Transfer Agent

American Stock Transfer and Trust

Auditor

Ernst & Young LLP

Legal Counsel

Latham & Watkins LLP

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

SEC Filings

Filing date Form Description Filing Group
S-3

Simplified registration form

Registration Statements
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Data Provided by Refinitiv. Minimum 15 minutes delayed.